Does the media prefer NVCT or CRBU?

In the previous week, Nuvectis Pharma had 16 more articles in the media than Caribou Biosciences. MarketBeat recorded 18 mentions for Nuvectis Pharma and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.77 beat Nuvectis Pharma's score of 0.30 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MPLT or CRBU?

In the previous week, Maplight Therapeutics had 3 more articles in the media than Caribou Biosciences. MarketBeat recorded 5 mentions for Maplight Therapeutics and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.77 beat Maplight Therapeutics' score of 0.55 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALT or CRBU?

In the previous week, Altimmune had 3 more articles in the media than Caribou Biosciences. MarketBeat recorded 5 mentions for Altimmune and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.77 beat Altimmune's score of 0.15 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRBU or STTK?

In the previous week, Shattuck Labs had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 3 mentions for Shattuck Labs and 2 mentions for Caribou Biosciences. Shattuck Labs' average media sentiment score of 0.90 beat Caribou Biosciences' score of 0.77 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Caribou Biosciences (CRBU) Competitors

$1.66 +0.01 (+0.61%)

As of 04:00 PM Eastern

Compare

CRBU vs. AVTE, NVCT, MPLT, ALT, and STTK

Should you buy Caribou Biosciences stock or one of its competitors? Caribou Biosciences's main competitors and comparable companies include Aerovate Therapeutics (AVTE), Nuvectis Pharma (NVCT), Maplight Therapeutics (MPLT), Altimmune (ALT), and Shattuck Labs (STTK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Caribou Biosciences compare to Aerovate Therapeutics?

Caribou Biosciences (NASDAQ:CRBU) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Aerovate Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Caribou Biosciences' return on equity of -84.17% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Caribou Biosciences presently has a consensus target price of $8.67, indicating a potential upside of 422.09%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Caribou Biosciences is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

77.5% of Caribou Biosciences shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aerovate Therapeutics has lower revenue, but higher earnings than Caribou Biosciences. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	14.75	-$148.12M	-$1.42	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

In the previous week, Caribou Biosciences had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Caribou Biosciences and 0 mentions for Aerovate Therapeutics. Caribou Biosciences' average media sentiment score of 0.77 beat Aerovate Therapeutics' score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Caribou Biosciences	Positive
Aerovate Therapeutics	Neutral

Caribou Biosciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Summary

Caribou Biosciences beats Aerovate Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Caribou Biosciences compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Nuvectis Pharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market.

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Nuvectis Pharma had 16 more articles in the media than Caribou Biosciences. MarketBeat recorded 18 mentions for Nuvectis Pharma and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.77 beat Nuvectis Pharma's score of 0.30 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Caribou Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvectis Pharma has higher earnings, but lower revenue than Caribou Biosciences. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Caribou Biosciences	$11.16M	14.75	-$148.12M	-$1.42	N/A

Nuvectis Pharma presently has a consensus price target of $35.00, indicating a potential upside of 85.38%. Caribou Biosciences has a consensus price target of $8.67, indicating a potential upside of 422.09%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Nuvectis Pharma has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Caribou Biosciences' return on equity of -84.17% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

Summary

Caribou Biosciences beats Nuvectis Pharma on 8 of the 14 factors compared between the two stocks.

How does Caribou Biosciences compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

77.5% of Caribou Biosciences shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Maplight Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Maplight Therapeutics' return on equity of 0.00% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

Maplight Therapeutics currently has a consensus target price of $31.17, indicating a potential upside of 155.88%. Caribou Biosciences has a consensus target price of $8.67, indicating a potential upside of 422.09%. Given Caribou Biosciences' higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Caribou Biosciences has higher revenue and earnings than Maplight Therapeutics. Caribou Biosciences is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Caribou Biosciences	$11.16M	14.75	-$148.12M	-$1.42	N/A

In the previous week, Maplight Therapeutics had 3 more articles in the media than Caribou Biosciences. MarketBeat recorded 5 mentions for Maplight Therapeutics and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.77 beat Maplight Therapeutics' score of 0.55 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caribou Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Maplight Therapeutics beats Caribou Biosciences on 8 of the 15 factors compared between the two stocks.

How does Caribou Biosciences compare to Altimmune?

Altimmune (NASDAQ:ALT) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

In the previous week, Altimmune had 3 more articles in the media than Caribou Biosciences. MarketBeat recorded 5 mentions for Altimmune and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.77 beat Altimmune's score of 0.15 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caribou Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Altimmune currently has a consensus target price of $15.71, suggesting a potential upside of 415.22%. Caribou Biosciences has a consensus target price of $8.67, suggesting a potential upside of 422.09%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Altimmune has higher earnings, but lower revenue than Caribou Biosciences. Altimmune is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,828.34	-$88.09M	-$0.93	N/A
Caribou Biosciences	$11.16M	14.75	-$148.12M	-$1.42	N/A

Altimmune has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market.

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Caribou Biosciences has a net margin of -1,189.14% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

Summary

Caribou Biosciences beats Altimmune on 9 of the 17 factors compared between the two stocks.

How does Caribou Biosciences compare to Shattuck Labs?

Caribou Biosciences (NASDAQ:CRBU) and Shattuck Labs (NASDAQ:STTK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Caribou Biosciences currently has a consensus price target of $8.67, suggesting a potential upside of 422.09%. Shattuck Labs has a consensus price target of $12.63, suggesting a potential upside of 76.82%. Given Caribou Biosciences' higher possible upside, research analysts clearly believe Caribou Biosciences is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Shattuck Labs has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Shattuck Labs' return on equity of -60.73% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
Shattuck Labs	N/A	-60.73%	-55.75%

Shattuck Labs has lower revenue, but higher earnings than Caribou Biosciences. Shattuck Labs is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	14.75	-$148.12M	-$1.42	N/A
Shattuck Labs	$1M	547.50	-$48.81M	-$0.63	N/A

In the previous week, Shattuck Labs had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 3 mentions for Shattuck Labs and 2 mentions for Caribou Biosciences. Shattuck Labs' average media sentiment score of 0.90 beat Caribou Biosciences' score of 0.77 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caribou Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caribou Biosciences has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 8.8% of Shattuck Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Shattuck Labs beats Caribou Biosciences on 11 of the 16 factors compared between the two stocks.

Get Caribou Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBU vs. The Competition

Export

Metric	Caribou Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$163.65M	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.17	9.13	269.75	24.74
Price / Sales	14.75	1,274.20	652.34	108.60
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	1.27	17.66	11.27	6.42
Net Income	-$148.12M	-$13.25M	$3.45B	$347.12M
7 Day Performance	10.67%	5.36%	3.56%	2.48%
1 Month Performance	-13.77%	-1.74%	-0.58%	-1.04%
1 Year Performance	-4.05%	61.36%	77.52%	23.22%

Caribou Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBU Caribou Biosciences	1.9272 of 5 stars	$1.66 +0.6%	$8.67 +422.1%	-4.6%	$163.65M	$11.16M	N/A	100	Upcoming Earnings
AVTE Aerovate Therapeutics	N/A	$19.75 -1.3%	N/A	+193.2%	$572.45M	N/A	N/A	20	Gap Up High Trading Volume
NVCT Nuvectis Pharma	3.9242 of 5 stars	$21.60 +0.4%	$35.00 +62.0%	+215.8%	$570.83M	N/A	N/A	8	Earnings Report
MPLT Maplight Therapeutics	3.3979 of 5 stars	$12.55 -3.6%	$34.42 +174.2%	N/A	$554.89M	N/A	N/A	109	Analyst Downgrade Gap Down
ALT Altimmune	2.0975 of 5 stars	$3.00 +5.6%	$15.71 +423.8%	-10.7%	$552.31M	$40K	N/A	50	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBU) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Caribou Biosciences (CRBU) Competitors

CRBU vs. AVTE, NVCT, MPLT, ALT, and STTK

How does Caribou Biosciences compare to Aerovate Therapeutics?

Summary

How does Caribou Biosciences compare to Nuvectis Pharma?

Summary

How does Caribou Biosciences compare to Maplight Therapeutics?

Summary

How does Caribou Biosciences compare to Altimmune?

Summary

How does Caribou Biosciences compare to Shattuck Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU vs. The Competition

Caribou Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Caribou Biosciences (CRBU) Competitors

CRBU vs. AVTE, NVCT, MPLT, ALT, and STTK

How does Caribou Biosciences compare to Aerovate Therapeutics?

Is CRBU or AVTE more profitable?

Do analysts recommend CRBU or AVTE?

Do institutionals & insiders have more ownership in CRBU or AVTE?

Which has higher valuation & earnings, CRBU or AVTE?

Does the media refer more to CRBU or AVTE?

Which has more risk & volatility, CRBU or AVTE?

Summary

How does Caribou Biosciences compare to Nuvectis Pharma?

Which has more risk and volatility, NVCT or CRBU?

Do institutionals and insiders have more ownership in NVCT or CRBU?

Does the media prefer NVCT or CRBU?

Which has higher valuation & earnings, NVCT or CRBU?

Do analysts prefer NVCT or CRBU?

Is NVCT or CRBU more profitable?

Summary

How does Caribou Biosciences compare to Maplight Therapeutics?

Do institutionals and insiders have more ownership in MPLT or CRBU?

Is MPLT or CRBU more profitable?

Do analysts rate MPLT or CRBU?

Which has preferable valuation and earnings, MPLT or CRBU?

Does the media prefer MPLT or CRBU?

Summary

How does Caribou Biosciences compare to Altimmune?

Does the media prefer ALT or CRBU?

Do analysts rate ALT or CRBU?

Which has better earnings & valuation, ALT or CRBU?

Which has more risk & volatility, ALT or CRBU?

Do institutionals and insiders hold more shares of ALT or CRBU?

Is ALT or CRBU more profitable?

Summary

How does Caribou Biosciences compare to Shattuck Labs?

Do analysts prefer CRBU or STTK?

Is CRBU or STTK more profitable?

Which has preferable valuation and earnings, CRBU or STTK?

Does the media favor CRBU or STTK?

Which has more risk & volatility, CRBU or STTK?

Do insiders and institutionals believe in CRBU or STTK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU vs. The Competition

Caribou Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools